The Synergo System is a computer-embedded intravesical irrigation system combined with an energy-delivering unit. The System includes an RF generator that delivers radio-frequency energy (the lower limit of microwave electromagnetic radiation) at 915 MHz, a drug circulating unit, and a microprocessor with application specific software. The user interface consists of a computer, monitor with touch screen, keyboard, and bar-code reader. Application specific software monitors and records treatment parameters during an actual session and provides a user interface that instantly alerts the user if parameters are out-of-range. A sterile triple lumen, silicone, transurethral Foley catheter is used for drug intravesical instillation. It has thermocouples for bladder wall temperature monitoring, and an RF antenna that radiates the bladder walls, causing phenotypical changes selectively in cancerous cells, creates membrane micro-poring (“Tunnelling Nano-Tubes”) and metabolic changes in these cells to increase the uptake of the drug, enhances drug mobility (becomes an active diffusion) through Foucault currents, and last but not least, generates heat at the target tissue at the desired, controlled temperature (hyperthermia) which is a synergistic protagonist.
Medical Enterprises Group is a growing and dynamic medical device company. It has its headquarters in Amsterdam, The Netherlands, where sales and marketing activities are managed. Research and Development, technical support and clinical activities are managed from the facility in Israel. Our R&D staff is a multifunctional team composed of physicists, electrical and mechanical engineers, software and QA experts. The medical department includes trained physicians who provide medical support to Urology Departments around the world, and handle clinical trials and publications.
The company is focused on developing minimally invasive therapeutic technologies which provide benefits for both patient and healthcare system.
The company's leading product, Synergo®, offers an advanced treatment modality for patients suffering from non-muscle invasive bladder cancer.